ASH 2022 | Impact of recent bendamustine treatment before apheresis on CAR-T therapy outcomes in LBCL
Gloria Iacoboni
• 12 Dec 2022
Gloria Iacoboni, MD, Vall d’Hebron University Hospital, Barcelona, Spain, presents results from a retrospective multicenter study that assessed the impact of previous bendamustine exposure on the outcomes of patients with large B-cell lymphoma (LBCL) receiving treatment with CAR-T therapy. This study demonstrated that patients with exposure to bendamustine within the last nine months before apheresis had worse outcomes than those with earlier exposure. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
